• Aging Lens Epithelium’s Susceptibility to Ferroptosis Uncove

  2026-06-02

  Wei et al. provide the first direct evidence that human and mouse lens epithelial cells (LECs) become increasingly vulnerable to ferroptosis with age, implicating this cell death pathway in cataractogenesis. Their work pinpoints redox imbalance and iron dysregulation as key drivers, suggesting new avenues for mechanistic studies and therapeutic intervention.

• Biotin-azide (A8013): Reliable Biotinylation for Click Chemi

  2026-06-02

  Discover how Biotin-azide (SKU A8013) from APExBIO delivers reproducible, high-purity biotin labeling for alkynylated biomolecules—empowering sensitive, bio-orthogonal workflows in cell viability and protein interaction studies. This scenario-driven guide addresses real bench challenges, provides protocol parameters, and benchmarks Biotin-azide against alternatives to accelerate reliable assay results.

• Tomivosertib Suppresses Human DRG Neuron Hyperactivity in Ra

  2026-06-01

  The study demonstrates that tomivosertib, a selective MNK inhibitor, rapidly and reversibly suppresses spontaneous activity in human dorsal root ganglion neurons from patients with radiculopathy. These results establish a direct mechanistic link between MNK signaling and neuropathic pain, supporting MNK inhibition as a promising translational strategy for pain intervention.

• Mechanistic Blueprint of ZAK Activation at Collided Ribosome

  2026-06-01

  This study delineates how ribosome collisions activate the MAP3K ZAK, a critical step in the ribotoxic stress response, by uncovering the structural and biochemical determinants of ZAK–ribosome interactions. These findings provide new mechanistic insight into kinase regulation during translational stress, with implications for cancer and cellular stress research.

• HIV-1 Infection Sensitizes Brain Pericytes to Glutamate via

  2026-05-31

  This study reveals that HIV-1 infection and latency compromise the DNA damage response in human brain vascular pericytes, making them more vulnerable to neuroinflammatory stressors such as extracellular glutamate and TNFα. The findings provide mechanistic insight into how pericyte dysfunction may contribute to blood-brain barrier breakdown in HIV-associated neurocognitive disorders and highlight DNA repair pathways as a potential research focus.

• RG108 DNA Methyltransferase Inhibitor: Protocols and Insight

  2026-05-30

  RG108 offers precise, non-covalent DNA methyltransferase inhibition, enabling robust epigenetic gene regulation studies with minimal cytotoxicity. Discover optimized workflows, troubleshooting strategies, and direct application guidance for using RG108 in advanced cancer and gene reactivation research.

• EPZ-6438: Mechanistic Leverage for Translational Epigenetic

  2026-05-29

  Explore how EPZ-6438, a potent and selective EZH2 inhibitor, is transforming the translational research landscape in epigenetic oncology. This thought-leadership article integrates mechanistic insight with strategic guidance, highlighting best practices, clinical potential, and future frontiers for researchers harnessing the PRC2 pathway.

• 2-APB: Advancing Calcium Signaling and PCD Research Workflow

  2026-05-29

  2-APB (2-aminoethoxydiphenyl borate) delivers unmatched precision in dissecting calcium-dependent autophagy and apoptosis, enabling robust, reproducible assays from cell culture to animal models. Leverage APExBIO’s trusted compound for reliable store-operated calcium entry inhibition and dynamic modulation of oxidative stress-related pathways.

• LNP-Stabilized Emulsions Enable Precise mRNA Delivery and Po

  2026-05-28

  Zhou et al. introduce a lipid nanoparticle-stabilized emulsion (LSE) system that biases mRNA delivery toward antigen-presenting cells, achieving enhanced spatiotemporal control over antigen expression and robust, durable T cell responses. This approach addresses the limitations of conventional LNPs by minimizing off-target antigen expression and T cell exhaustion, setting a new standard for mRNA vaccine engineering.

• Evaluating Cancer Drug Responses: Advances in In Vitro Metho

  2026-05-28

  Schwartz's doctoral dissertation introduces a nuanced approach to in vitro evaluation of anti-cancer drugs, distinguishing between proliferative arrest and cell death to improve experimental interpretation. This work advances assay strategy, clarifies response metrics, and impacts the design of studies involving agents such as Wee1 kinase inhibitors.

• HOBt (1-Hydroxybenzotriazole): Precision Tool for Amide Bond

  2026-05-27

  HOBt (1-Hydroxybenzotriazole) is a cornerstone reagent in peptide synthesis, enabling high-fidelity amide bond formation by minimizing epimerization. Its utility extends to the preparation of complex bioactive molecules, with rigorous evidence supporting its mechanism and benchmarks in modern workflows.

• Abiraterone Acetate: Optimizing CYP17 Inhibition in 3D Prost

  2026-05-27

  Harness the full translational power of Abiraterone acetate—a potent CYP17 inhibitor—with actionable workflows for cutting-edge 3D prostate cancer models. Learn how to refine protocols, enhance model realism, and troubleshoot common pitfalls in androgen biosynthesis pathway research.

• SC 79: Akt Activator Workflows for Neuroprotection & Cancer

  2026-05-26

  SC 79 is redefining how researchers probe the Akt pathway, enabling cytosolic activation and robust neuroprotection in ischemic models, while also serving as a mechanistic tool in cancer biology studies. This guide delivers actionable protocols, troubleshooting, and context from recent ferroptosis research to maximize SC 79’s impact across neuroscience and oncology.

• Anlotinib Hydrochloride in IADSRCT: Case Report and Research

  2026-05-26

  This article reviews the first documented use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in the treatment of intra-abdominal desmoplastic small round cell tumor (IADSRCT). The case study and literature context highlight both the clinical promise and the translational research opportunities of targeting angiogenesis in rare, aggressive malignancies.

• Quizartinib (AC220): Optimizing FLT3 Inhibition in AML Model

  2026-05-25

  Quizartinib (AC220) empowers acute myeloid leukemia (AML) research by delivering potent, selective FLT3 inhibition at nanomolar concentrations. This guide details experimental workflows, troubleshooting strategies, and the translational value of Quizartinib for dissecting FLT3-driven disease and resistance.

15925 records 1/1062 page Next 12345 下5页 Last page